

PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

14772 U.S. PRO
10/607521
06/26/03

Mail Stop Patent Application
Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2002/0044US NP

INVENTORS: Stefan Schäfer, et al

TITLE: Use of Vasopeptidase Inhibitors in the Treatment of Metabolic Diseases, Nephropathy and Advanced Glycation End-Product Associated Diseases

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

6-26-03
Date of Deposit

Bonnie Stein
Signature

EV 069262006 US
Express Mail No.

APPLICATION ELEMENTS

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i>	Total Pages	<input type="text" value="38"/>
2. <input checked="" type="checkbox"/> Specification <i>(preferred arrangement set forth below)</i> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	<input type="text" value="38"/>
3. <input checked="" type="checkbox"/> Drawing(s) <i>(35 U.S.C. 113)</i>	Total Sheets	<input type="text" value="1"/>
4. Oath or Declaration	Total Pages	<input type="text" value="2"/>
a. <input checked="" type="checkbox"/> Newly <u>unexecuted</u> (original or copy)		
b. <input type="checkbox"/> Copy from a prior application <i>(37 CFR § 1.63(d))</i>		
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		
5. Power of Attorney	Total Pages	<input type="text"/>
a. <input type="checkbox"/> Newly executed (original or copy)		
b. <input type="checkbox"/> Copy from a prior application <i>(37 CFR § 1.63(d))</i>		
6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i>		

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

- a. Computer Readable Copy
- b. Paper Copy (identical to computer copy)
- c. Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: _____, filed _____,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims priority from German Application No. 10229180.2-41, filed June 28, 2002 and claims the benefit of U.S. Provisional Application No. 60/423,590, filed November 4, 2002.

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS

- 7. Assignment Papers (cover sheet & document(s))
- 8. 37 CFR §3.73(b) Statement
(when there is an assignee)
- 9. Verified English Translation Document (if applicable)
- 10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
- 11. Preliminary Amendment
- 12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
- 14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
- 15. Other: Application Data Sheet

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label



Lawrence L. Martin

Lawrence L. Martin, Reg. No. 46,902
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626
Aventis Docket No. **DEAV2002/0044US NP**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

for FY 2003

Patent fees are subject to annual revision.


Complete if Known

Application Number	T Be Assigned
Filing Date	Filed Concurrently Herewith
First Named Inventor	Stefan Schaf r, t al
Examiner Name	T Be Assigned
Group / Art Unit	T Be Assigned
Attorney Docket No.	DEAV2002/0044US NP

 Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 930.00)

METHOD OF PAYMENT (check all that apply)					FEE CALCULATION (continued)					
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account					3. ADDITIONAL FEES					
Deposit Account Number 18-1982 Deposit Account Name Aventis Pharmaceuticals Inc. The Commissioner is authorized to: (check all that apply) <input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account					Large Entity Small Entity					
					Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
					1051	130	2051	65	Surcharge - late filing fee or oath	
					1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
					1053	130	1053	130	Non-English Specification	
					1812	2,520	1812	2,520	For filing a request for reexamination	
					1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
					1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
					1251	110	2251	55	Extension for reply within first month	
					1252	410	2252	205	Extension for reply within second month	
					1253	930	2253	465	Extension for reply within third month	
					1254	1,450	2254	725	Extension for reply within fourth month	
					1255	1970	2255	985	Extension for reply within fifth month	
					1401	320	2401	160	Notice of Appeal	
					1402	320	2402	160	Filing a brief in support of an appeal	
					1403	280	2403	140	Request for oral hearing	
					1451	1,510	1451	1,510	Petition to institute a public use proceeding	
					1452	110	2452	55	Petition to revive - unavoidable	
					1453	1,300	2453	650	Petition to revive - unintentional	
					1501	1,300	2501	650	Utility issue fee (or reissue)	
					1502	470	2502	235	Design issue fee	
					1503	630	2503	315	Plant issue fee	
					1460	130	1460	130	Petitions to the Commissioner	
					1807	50	1807	50	Petitions related to provisional applications	
					1806	180	1806	180	Submission of Information Disclosure Stmt	
					8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
					1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
					1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
					1801	750	2801	375	Request for Continued Examination (RCE)	
					1802	900	1802	900	Request for expedited examination of a design application	
					Other fee (specify) _____					
					*Reduced by Basic Filing Fee Paid					SUBTOTAL (3) (\$)

*or number previously paid, if greater; For Reissues, see above

SUBMITTED BY						Complete (If applicable)	
Name (Print/Type)	Lawrence L. Martin, Reg. No. 46,902		Registration No. (Attorney/Agent)	46,902	Telephone	(908) 231-4803	
Signature					Date	6/26/2003	

WARNING: Information on this form may become public. Credit card information is handled in this form. Provide credit card information and authorization in PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template